ASSESSMENT OF BIOENERGETIC PROCESSES IN MITOCHONDRIA IN IN VIVO MODELS OF PARKINSON'S DISEASE

  • Feruza TOLLIBOYEVA O‘zbekiston Milliy universiteti tayanch doktaranti
  • Nafisa KOMILOVA O‘zbekiston Milliy universiteti PhD, Biofizika kafedrasi o‘qituvchisi
  • Ulug‘bek MIRXODJAEV vO‘zbekiston Milliy universiteti Biofizika kafedrasi professori
Keywords: Parkinson kasalligi (PK), rotenon , oksidlanishli fosforlanish , ATF, ADF

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease associated with movement disorders [1]. Although general treatment measures for PK have not been fully developed, some progress has been made in the symptomatic treatment of the disease. The heterogeneity of PK due to the age of onset and the causes of its origin requires the diversity of models that fully reveal the characteristics of the disease. One of the priority tasks during experiments is to choose and create models that can fully reveal all the signs of clinical PK. Currently, animal models are the best tool for studying the pathogenesis of PK. During our experiments, methods of creating an in vivo model of Parkinson's disease in animals and correctly evaluating the motor movements occurring in the models were considered.

References

v1. Timothy R. Mhyre,corresponding author James T. Boyd, Robert W. Hamill, and Kathleen A. Maguire-Zeiss. Parkinson’s Disease. Subcell Biochem. 2012; 65: 389–455.
2. Claudia M Testa, Todd B Sherer, J Timothy Greenamyre Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures Brain Res Mol Brain Res 2005 Mar 24;134(1):109-18
3. Jason R Cannon , Victor Tapias, Hye Mee Na, Anthony S Honick, Robert E Drolet, J Timothy Greenamyre (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis. 34(2): 279–290.
4. J M Gorell 1, C C Johnson, B A Rybicki, E L Peterson, R J Richardson. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998 ;50(5):1346-50
5. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson’s disease. J Neurol. 2002 Feb;249(2):138–45.
6. Kevin M. Gamber. Animal Models of Parkinson's Disease: New models provide greater translational and predictive value. Biotechniques vol. 61, no. 4 . Published Online:16 Mar 2018
7. J Timothy Greenamyre 1, Teresa G Hastings. Parkinson's--divergent causes, convergent mechanisms. Science. 2004 May 21;304(5674):1120-2.
8. Betarbet R, Sherer TB, MacKenzie G, Gracia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000 Dec;3(12):1301–6
9. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of parkinson's disease. J Neurosci. 2003; 23(34):10756–10764.
10. Simon P Brooks 1, Stephen B Dunnett . Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci 2009 Jul;10(7):519-29.
11. Robert M.J. Deacon. Measuring the Strength of Mice. Journal of Visualized Experiments. 2013; (76): 2610.
12. Ignacio A, Javier T, Carlos BR. Isolating brain mitochondria by differential centrifugation. Bio-protocol. 2016; 6 (10): e1810. DOI: 10.21769/BioProtoc.1810.
Published
2024-03-29
How to Cite
Feruza TOLLIBOYEVA, Nafisa KOMILOVA, & Ulug‘bek MIRXODJAEV. (2024). ASSESSMENT OF BIOENERGETIC PROCESSES IN MITOCHONDRIA IN IN VIVO MODELS OF PARKINSON’S DISEASE. News of the NUUz, 3(3.1), 149-152. https://doi.org/10.69617/uzmu.v3i3.1.1748